Walgreens Agrees to $23.7 Billion Buyout by Sycamore Partners
Deal News | May 23, 2025 | EIN

Sycamore Partners, a private equity firm known for its focus on the retail and consumer sectors, has entered into a merger agreement to acquire Walgreens Boots Alliance for approximately $23.7 billion, marking a significant leveraged buyout in recent years. The transaction is slated to close by the end of 2025, transitioning Walgreens from a public to a private company, with a goal to enhance the company's agility in adapting to modern healthcare retail dynamics. Walgreens has faced challenges from e-commerce giants, leading to this strategic move to refocus its business operations. Shareholders will receive a cash payout of $11.45 per share, and potentially an additional $3.00 per share contingent on future divestments of Walgreens’ interests in VillageMD. The merger includes a go-shop provision, allowing Walgreens to seek alternative offers within a set period, although board obligations are limited regarding disclosures during this timeframe. Termination fees are structured within the merger agreement to address potential withdrawal scenarios, with Sycamore securing financing commitments to back the acquisition.
Sectors
- Pharmacy and Retail
- Private Equity
- Healthcare Services
Geography
- United States – Walgreens is headquartered in Chicago, and Sycamore Partners is based in New York, with the transaction impacting the U.S. market.
- Global – Walgreens, being a significant global player in the pharmacy sector, impacts the international market beyond the United States.
Industry
- Pharmacy and Retail – Walgreens is involved primarily in the pharmacy retail sector, and the acquisition is centered around repositioning its operations within this industry.
- Private Equity – Sycamore Partners, acting as the acquiring entity, operates within the private equity industry, focusing on retail and consumer investments.
- Healthcare Services – The reference to Walgreens’ operations including pharmacy and VillageMD’s healthcare services highlights the relevance of this sector.
Financials
- $23.7 billion – The total acquisition value of Walgreens by Sycamore Partners.
- $11.45 per share – Cash payout per share for Walgreens shareholders as part of the acquisition.
- Up to $3.00 per share – Additional potential payout per share contingent on the divestment of interest in VillageMD.
- $560 million – Buyer termination fee outlined in the merger agreement.
- $158 million – Fee Walgreens must pay if it terminates the merger during the go-shop period for a superior offer.
- $316 million – Termination fee if Walgreens ends the merger agreement outside the go-shop conditions.
Participants
Name | Role | Type | Description |
---|---|---|---|
Walgreens Boots Alliance | Target | Company | A major pharmacy retail chain in the U.S. agreeing to a buyout by Sycamore Partners. |
Sycamore Partners | Acquirer | Company | A private equity firm focusing on retail and consumer sectors, acquiring Walgreens to enhance its operations. |
Tim Wentworth | CEO | People | CEO of Walgreens, who supports the transaction as beneficial for the company’s strategic focus. |
Stefano Pessina | Executive Chairman | People | Executive Chairman of Walgreens, owning a significant share, committed to supporting the transaction. |
VillageMD | Affiliated Company | Company | A value-based primary care chain partially owned by Walgreens, mentioned in divestment plans. |